{"name":"H-CYTE","slug":"h-cyte","ticker":"","exchange":"","domain":"","description":"H-CYTE is a biotechnology company focused on developing innovative cellular therapies. The company's lead product, Autologous Cellular Therapy with PRP-PC, is currently in Phase 2 clinical trials. Despite significant R&D investment, the company reported a net loss in the latest fiscal year.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":207396,"revenueGrowth":527.6,"grossMargin":0,"rdSpend":2038204,"netIncome":-10299580,"cash":137357,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Autologous Cellular Therapy with PRP-PC","genericName":"Autologous Cellular Therapy with PRP-PC","slug":"autologous-cellular-therapy-with-prp-pc","indication":"Musculoskeletal injuries and degenerative conditions","status":"phase_2"}]}],"pipeline":[{"name":"Autologous Cellular Therapy with PRP-PC","genericName":"Autologous Cellular Therapy with PRP-PC","slug":"autologous-cellular-therapy-with-prp-pc","phase":"phase_2","mechanism":"Autologous Cellular Therapy with PRP-PC involves using a patient's own cells, combined with platelet-rich plasma and platelet concentrate, to stimulate healing and tissue repair.","indications":["Musculoskeletal injuries and degenerative conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2025-01-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2024-08-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2024-07-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2024-06-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2024-06-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2024-05-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2024-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2024-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2024-02-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-12-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-11-15","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":207396,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":207396,"period":"2017-12-31"},{"value":33045,"period":"2015-12-31"},{"value":0,"period":"2014-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":2038204,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-10299580,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":137357,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}